Clearmind Medicine announces shareholders meeting results

Clearmind Medicine (CMND) announced that all of the matters put forward before shareholders for consideration and approval at its meeting held on January 6, 2025, as set out in the Company’s Management Information Circular dated December 1, 2024, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at five members, the election of directors of the Company for the ensuing year, to appoint Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network, as auditor of the Company, a resolution to establish and approve an omnibus equity incentive plan and a resolution allowing the directors, if they deem such an action to be in the best interest of shareholders, effect a consolidation of the common shares in the capital of the Company on the basis of fifty pre-Consolidation Shares for one post-Consolidation Share, or such other lesser consolidation ratio as determined by the Company’s board of directors.